Pfizer Inc. (NYSE:PFE) Stake Boosted by FIL Ltd

FIL Ltd increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 28.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,788,512 shares of the biopharmaceutical company's stock after acquiring an additional 1,512,801 shares during the period. FIL Ltd owned approximately 0.12% of Pfizer worth $180,099,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the 4th quarter valued at about $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer during the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer in the fourth quarter valued at about $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer during the 4th quarter valued at approximately $31,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 1.4 %

Shares of NYSE PFE traded up $0.30 during trading on Friday, hitting $21.89. 55,013,451 shares of the company traded hands, compared to its average volume of 40,232,439. The firm has a market capitalization of $124.14 billion, a P/E ratio of 15.52, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a 50-day moving average price of $25.25 and a 200-day moving average price of $26.38. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the previous year, the business earned $0.10 earnings per share. The firm's quarterly revenue was up 24.7% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on PFE. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. UBS Group cut their target price on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a research report on Tuesday, April 8th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and an average target price of $31.07.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.